[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 491
Citations 0
News From the Food and Drug Administration
August 16, 2016

New Drug Targets All 6 HCV Types

JAMA. 2016;316(7):703. doi:10.1001/jama.2016.10682

Joining the wave of recently approved hepatitis C virus (HCV) drugs that act directly on the virus is a tablet containing sofosbuvir, which was approved in 2013, and velpatasvir—the first drug to treat all 6 major forms of HCV infection (http://bit.ly/290Hwgp).

Marketed as Epclusa, the new medication is used with ribavirin only for patients with moderate to severe cirrhosis. Its “approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,” Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in a statement.

First Page Preview View Large
First page PDF preview
First page PDF preview
×